Compare ENVX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | EYPT |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2020 | 2005 |
| Metric | ENVX | EYPT |
|---|---|---|
| Price | $4.88 | $15.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $14.56 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.7M |
| Earning Date | 05-21-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,821,000.00 | $7,539,000.00 |
| Revenue This Year | $40.85 | N/A |
| Revenue Next Year | $236.84 | $965.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.84 | $3.91 |
| 52 Week High | $16.49 | $19.11 |
| Indicator | ENVX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 30.07 | 48.07 |
| Support Level | N/A | $11.88 |
| Resistance Level | $8.73 | $19.06 |
| Average True Range (ATR) | 0.37 | 1.43 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 0.94 | 50.31 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.